This document discloses a novel class of quinazoline EGFR inhibitors. Also disclosed are pharmaceutical compositions thereof and method for treating cancers. Disclosed herein is a novel class of quinazoline compounds which selectively and effectively inhibit the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor (EGFR).La présente invention concerne une nouvelle classe d'inhibiteurs de l'EGFR quinazoline. L'invention concerne également des compositions pharmaceutiques associées et une méthode de traitement de cancers.